BioNexus Gene Lab Corp
bionexusgenelab.comWhat Do They Do?
Distributes chemical raw materials to manufacturers across Southeast Asia and provides blood-based genomic screening services to healthcare providers.
10-K for FY2025, filed Apr 14, 2026BioNexus Gene Lab Corp. is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd.…View ↗
The Company, through its wholly owned subsidiary Chemrex, focuses on the sale of chemical raw materials for the manufacture of industrial…View ↗
Chemrex, our wholly owned subsidiary, is involved in the wholesale of chemical raw material products. We purchase raw chemical materials…View ↗
We generate revenue by screening blood samples collected by third-party healthcare providers including doctors, labs, and hospitals using…View ↗
How Do They Make Money?
Manufacturers buy chemical raw materials, while healthcare providers pay for genomic screening services. Chemical sales have credit terms generally from 30 to 90 days; screening services have terms generally from 30 days to 60 days.
10-K for FY2025, filed Apr 14, 2026Chemrex, our wholly owned subsidiary, is involved in the wholesale of chemical raw material products. We purchase raw chemical materials…View ↗
We generate revenue by screening blood samples collected by third-party healthcare providers including doctors, labs, and hospitals using…View ↗
Revenue is derived from the sale of industrial chemicals and the provision of genomic screening services. Revenue from the sale of goods is…View ↗
Revenue from services is recognized at a point in time when the final report is delivered to the customer. Credit terms for these services…View ↗
$7.4M
-
10-K for FY2025, filed Apr 14, 2026
$7.4M ↗
Who Are Their Customers?
Manufacturers, fabricators and contractors buy chemical materials from Chemrex, typically forecasting their needs and placing orders monthly. Doctors, laboratories and hospitals provide blood samples for MRNA Scientific’s screening services.
10-K for FY2025, filed Apr 14, 2026Chemrex’s customers are primarily manufacturers, fabricators, and contractors. Many of these customers are repeat customers with whom…View ↗
We generate revenue by screening blood samples collected by third-party healthcare providers including doctors, labs, and hospitals using…View ↗
MRNA Scientific’s screening process generally begins with a blood sample collected by a licensed healthcare provider and delivered to the…View ↗
Do Revenues Turn Into Profits?
No. It lost $3M in FY2025.
10-K for FY2025, filed Apr 14, 2026
−$3MView ↗
10-K for FY2025, filed Apr 14, 2026
−$3MView ↗
10-K for FY2025, filed Apr 14, 2026
−$1.9MView ↗
How Are They Changing?
Shrinking. Revenue fell 44% in 4 years, from $13.4M in FY2021 to $7.4M in FY2025, about 14% a year.
Adding cancer monitoring
The latest report adds a licensed platform for monitoring cancer recurrence to the earlier description of blood tests that screen for disease risks.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Apr 14, 2026Furthermore, the Company is also in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the…View ↗
In November 2025, the Company completed a Share Subscription and Shareholders’ Agreement with Fidelion Diagnostics Pte. Ltd., a Singapore…View ↗
Loading...
